Freezing of Gait in Parkinson's Disease is Improved by Treatment with Weak Electromagnetic Fields

References

• Agid Y., Javoy-Agid F., Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. Movement Disorders, C. D. Marsden, S. Fahn. Butterworths, London 1987; 166–230
   Google Scholar
• Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Seuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Aldrich M. S. Narcolepsy. Neurology 1992; 42: 34–43, suppl 6
   PubMed Web of Science ®Google Scholar
• Aldrich M. S. The neurobiology of narcolepsy-cataplexy. Progress in Neurobiology 1993; 41: 533–541
   PubMed Web of Science ®Google Scholar
• Amatruda T. T., Black, Jr., McKenna D. A., McCarly R. W., Hobson J. A. Sleep cycle control and cholinergic mechanisms: differential effect of carbachol injections at pontine brainstem sites. Brain Research 1975; 98: 501–515
   PubMed Web of Science ®Google Scholar
• Ambani L. M., Van Woert M. H. Start hesitation-a side effect of long term levodopa therapy. New England Journal of Medicine 1973; 288: 1113–1115
   PubMed Web of Science ®Google Scholar
• Andrews C. J. Influence of dystonia on the response to long-term L-dopa therapy in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1973; 36: 630–636
   PubMed Web of Science ®Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effects of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Auff E., Birkmayer W., Brucke T., Deecke L., Emich C, Goldenberg G., Hirsch E., Maly J., Muller C, Potzl G., Riederer P., Sofic E., Schnaberth G. Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study. New Trends in Clinical Neuropharmacology 1987; 1: 149–158
   Google Scholar
• Baker T. L. Introduction to sleep and sleep disorders. Medical Clinics of North America 1985; 69: 1123–1152
   PubMed Web of Science ®Google Scholar
• Baldessarini R. J., Marsh E. R., Kula N. S. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Research 1992; 579: 152–156
   PubMed Web of Science ®Google Scholar
• Barbeau A. Biochemistry of Parkinson's disease. Neurology 1963; 13: 56–58
   PubMedGoogle Scholar
• Barbeau A. Contributions of levodopa therapy to the neuropharmacology of akinesia. Parkinson's Disease: Rigidity, Akinesia, Behavior, J. Siegfried. Hans Huber Publishing, Bern 1972; vol. I: 151–174
   Google Scholar
• Barbeau A. The clinical physiology of side effects in long term L-dopa therapy. Advances in Neurology, F. H. McDowell, A. Barbeau. Raven Press, New York 1974; 347–358
   Google Scholar
• Barbeau A., Jasmin G., Duchastel Y. Biochemistry of Parkinson's disease. Neurology 1963; 13: 56–58
   PubMedGoogle Scholar
• Baumgarten H. G., Lachenmayer L. Anatomical features and physiological properties of central serotonin neurons. Pharmacopsychiatrie 1985; 18: 180–187
   PubMed Web of Science ®Google Scholar
• Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA 1976; 73, 1999–2003
   PubMed Web of Science ®Google Scholar
• Bernheimer H., Birkmayer W., Homykiewicz O. Verteilung des 5-hydroxytryptamins (Serotonin) in Gehirn des Menscnen und sein Verhalten bein Patienten mit Parkinson Syndrome. Klinische Wochenschrift 1961; 39: 1056–1059
   PubMedGoogle Scholar
• Blackman C. F. Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. Electromagnetic Fields andNeurobehavioral Function, M. E. O'Connor, R. H. Lovely. Alan R. Liss, New York 1988
   Google Scholar
• Bouchard R. H., Pourcher E., Vincet P. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 1989; 146: 1352–1353
   Web of Science ®Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. The Pineal Gland: Endocrine Aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Brunello N., Barabaccia M. L., Chuang D. M., Costa E. Down-regulation of beta-adrenergic receptors following repeated injections of desmethylimipramine. Permissive role of serotonergic neurons. Neuropharmacoogy 1982; 21: 1145–1149
   PubMed Web of Science ®Google Scholar
• Burton S., Daya S., Potgieter B. Melatonin modulates apomorphine-induced rotational behaviour. Experientia 1991; 47: 466–469
   PubMedGoogle Scholar
• Cantello R., Aguggia M., Gilli M., Delsedime M., Chiardo Cutin I., Riccio A., Mutani R. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the “hedonic” dopamine synapse. Journal of Neurology Neurosurgery and Psychiatry 1989; 52: 724–731
   PubMed Web of Science ®Google Scholar
• Cardinali D. P. Changes in hypothalamic neurotransmitter uptake following pinealectomy, superior cervical ganglionectomy or melatonin administration to rats. Neuroendocrinology 1975; 19: 91–95
   PubMed Web of Science ®Google Scholar
• Chao L. L., Knight R. T. Human prefrontal lesions increase distractibility to irrelevant sensory input. Neuro Report 1995; 6: 1605–1610
   PubMed Web of Science ®Google Scholar
• Chase T. N. 5-hydroxytryptophan in parkinsonism. Lancet 1970; 2: 1029–1030
   PubMed Web of Science ®Google Scholar
• Chase T. N. Serotonergic mechanisms in Parkinson's disease. Archives of Neurology 1972; 27: 354–356
   PubMedGoogle Scholar
• Chase T. N. Serotoninergic mechanisms and extrapyramidal function in man. Advances in Neurology 1974; 5: 31–39
   PubMedGoogle Scholar
• Chase T. N., Schnur J. A., Gordon E. K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramial disorders. Neuropharmacology 1970; 9: 265–268
   PubMed Web of Science ®Google Scholar
• Chase T. N., Ng L. K. Y., Wanatabe A. M. Parkinson's disease. Modifications by 5-hydroxytryptophan. Neurology 1972; 22: 479–484
   PubMed Web of Science ®Google Scholar
• Cotzias G. C, Tang L. C, Miller S. T., Ginos J. Z. Melatonin and abnormal movement induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C, Pullar L. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Delwaide P. J., Gonce M. Pathophysiology of Parkinson's signs. Parkinson's Disease and Movement Disorders, J. Jankovic, E. Tolosa. Urban and Schwarzenberg, Baltimore 1988; 59–73
   Google Scholar
• Descarriers L., Beaudet A., Watkins K. C. Serotonin nerve terminals in adult rat neocortex. Brain Research 1975; 100: 563–588
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Dray A., Gonye T. J., Oakley N. R., Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Research 1976; 113: 45–57
   PubMed Web of Science ®Google Scholar
• Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y. Levodopa-induceddyskinesias are imporved by fluoxetine. Neurology 1995; 45: 1855–1858
   PubMed Web of Science ®Google Scholar
• Ennis C, Kemp J. D., Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. Journal of Neurochemistry 1981; 36: 1515–1520
   PubMed Web of Science ®Google Scholar
• Everett G. M., Borcherding J. W. L-dopa: effect on concentration of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970; 168: 849–850
   PubMed Web of Science ®Google Scholar
• Fahn S. Parkinsonism. Merritt's Textbook of Neurology 9th edition, L. P. Rowland. Williams and Wilkins, Baltimore 1995; 713–728
   Google Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. Journal of Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Fischer P. A., Baas H., Hefner R. Treatment of parkinsonian tremor with clozapine. Journal of Neural Transmission [P-D sect] 1990; 2: 233–238
   PubMed Web of Science ®Google Scholar
• Foutz A. S., Delashaw J. B., Guillenminault C., Dement W. C. Monoaminergic mechanisms and experimental cataplexy. Annals of Neurology 1981; 10: 369–376
   PubMed Web of Science ®Google Scholar
• Frey J., Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology 1994; 44: 707–709
   PubMed Web of Science ®Google Scholar
• Freyhan F. A. Psychomotility and parkinsonism in treatment with neuroleptic drugs. Archives of Neurology 1957; 78: 465–472
   Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29: 553
   Web of Science ®Google Scholar
• Gerstmann J., Schilder P. Ueber eine besondere Gangstoemng bein Stirnhirnerkrankung. Wien Medizinische Wochenschrift 1926; 76: 97–102
   Google Scholar
• Gschwend J. Der Haltetonus der Katze im Schlaf. Brain Research 1970; 22: 29–45
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B., Bedard P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clinical Neuropharmacology 1993; 16: 418–427
   PubMed Web of Science ®Google Scholar
• Guilleminault C. Cataplexy. Narcolepsy, C. Guilleminault, W. C. Dement, P. Passauant. Spectrum Publications, Inc, New York 1976; 125–143
   Google Scholar
• Guilleminault C, Dement W. C., Passouant P. Narcolepsy. Spectrum Publications, New York 1976; 684
   Google Scholar
• Gumbert J., Sharpe D., Curzon G. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. Journal of Neurological Sciences 1973; 19: 1–12
   PubMed Web of Science ®Google Scholar
• Hoehn M. M. Natural history of the untreated pre-levodopa disease. Parkinson's Disease, G Stern. Chapman and Hall Medical, London 1990; 307–311
   Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Hong J. S., Tilson H. A., Uphouse L. L., Gerhart J., Wilson W. E. Effects of chlordecone exposure on brain neurotransmitters: possible involvement of the serotonin system in chlordecone elicited tremor. Toxicology and Applied Pharmacology 1984; 73: 336–344
   PubMed Web of Science ®Google Scholar
• Hutt C. S., Snider S. R., Fahn S. Interaction between bromocriptine and levodopa. Neurology 1977; 27: 505–510
   Web of Science ®Google Scholar
• Ishizaki F., Nishikawa S. Relation of blood serotonin and benzylamine oxidase to clinical symptoms and prognosis in Parkinson's disease. European Neurology 1988; 28: 291–294
   PubMed Web of Science ®Google Scholar
• Jacobs B. L. Serotonin and behavior: emphasis on motor control. Journal of Clinical Psychiatry 1991; 52(12)17–23, (suppl)
   PubMed Web of Science ®Google Scholar
• Jacobs B. L. Serotonin, motor activity and depression-related disorders. American Scientist 1994; 82: 456–463
   Web of Science ®Google Scholar
• Jacobs B. L., Trulson M. E. Dreams, hallucinations, and psychosis- the serotonin connection. Trends in Neurosciences 1979; 11: 276–280
   Web of Science ®Google Scholar
• Jacobs B. L., Fornal C. A. 5-HT and motor control: a hypothesis. Trends in Neurosciences 1993; 16: 346–352
   PubMed Web of Science ®Google Scholar
• Jacobs B. L., Wilkinson L. O., Fornal C. A. The role of brain serotonin. A neurophysiologic perspective. Neuropsychopharmacology 1990; 3: 473–479
   PubMed Web of Science ®Google Scholar
• Jaffe R. A., Laszewski B. L., Carr D. B., Phillips R. D. Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics 1980; 1: 131–147
   PubMedGoogle Scholar
• Jankovic J. Pathophysiology and clinical assessment of motor symptoms in Parkinson's disease. Handbook of Parkinson's Disease, W. C. Roller. Marcel Dekker, New York 1987; 99–126
   Google Scholar
• Jankovic J. Lower body (vascular) parkinsonism. Archives of Neurology 1990; 47: 728
   PubMedGoogle Scholar
• Javoy-Agid F., Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease. Neurology 1980; 30: 1326–1330
   PubMed Web of Science ®Google Scholar
• Javoy-Agid F., Ploska A., Agid Y. Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brains. Journal of Neurochemistry 1981; 37: 1218–1227
   PubMed Web of Science ®Google Scholar
• Javoy-Agid F., Ruberg M., Taquet H., Bokobza B., Agid Y., Gaspar P., Berger B., N'Guyen-Legros J., Alvarez C, Gray F., Escourolle R., Scatton B., Rouquier L. Biochemical neuropathology of Parkinson's disease. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 189–198
   Google Scholar
• Johansson B., Roos B. E. 5-hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L-dopa. European Journal of Pharmacology 1971; 3: 232–235
   Web of Science ®Google Scholar
• Kanazawa I. Clinical pathophysiology of basal ganglia disease. Handbookof Clinical Neurology: extrapyramidal disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier, Amsterdam 1986; vol. 5: 65–85, 49
   Google Scholar
• Karobath M., Diaz J., Huttunen M. The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain. European Journal of Pharmacology 1971; 14: 393–396
   PubMed Web of Science ®Google Scholar
• Kelly D. D. Sleep and dreaming. Principles of Neural Science 3rd Edition, E. R. Kandel, J. H. Schwartz, T. M. Jessell. Elsevier, New York 1991; 792
   Google Scholar
• Kienzl E., Riederer P., Jellinger K., Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. Journal of Neural Transmission 1991; 51: 113–122
   Google Scholar
• Klawans H. L., Goetz C., Bergen D. Levodopa-induced myoclonus. Archives of Neurology 1975; 32: 331–334
   Google Scholar
• Kovacs G. L., Gayari I., Telegdy G., Lissak K. Effect of melatonin and pinealectomy on avoidance and exploratory activity in the rat. Physiology and Behavior 1974; 13: 349–355
   PubMed Web of Science ®Google Scholar
• Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurologica Scandinavica 1969; 45: 109
   PubMed Web of Science ®Google Scholar
• Llinas R. R., Pare D. Commentary of dreaming and wakefulness. Neuroscience 1991; 44: 521–535
   PubMed Web of Science ®Google Scholar
• Markianos M., Hadjikonstantinou M., Bistolaki E. Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment. Acta Neurologica Scandinavica 1982; 66: 267–275
   PubMed Web of Science ®Google Scholar
• Marsden C. D. On-Off phenomenon in Parkinson's disease. Parkinson's Disease-Current Progress, Problems and Management, U. K. Rinne, M. Klinger, G. Stamm. Elsevier/North-Holland Biomedical Press, Amsterdam 1980; 241–254
   Google Scholar
• Marsden C. D., Parkes J. D. “On-off” effects in patients with Parkinson's disease on chronic lev-odopa therapy. Lancet 1976; 1: 292–296
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Parkes J. D. On and off variability and response swings in Parkinson's disease. Research Progress in Parkinson's Disease, F. C. Rose, R. Capildeo. Pitman Medical, Kent 1980; 265–274
   Google Scholar
• Mayeux R., Stern Y., Cote L., Williams S. B. W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642–646
   PubMed Web of Science ®Google Scholar
• Maxwell D. J., Leranth C., Verhofstad A. A. J. Fine structure of serotonin-containing axons in the marginal zone of the rat's spinal cord. Brain Research 1983; 266: 253–259
   PubMed Web of Science ®Google Scholar
• McCall R. B., Aghajanian G. K. Serotonergic facilitation of facial motoneuron excitation. Brain Research 1979; 169: 11–27
   PubMed Web of Science ®Google Scholar
• McCance-Katz E. F., Marek K. L., Price L. H. Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42: 1813–1814
   PubMed Web of Science ®Google Scholar
• McGinty D. J., Harper R. M. Dorsal raphe neurons: depression of firing during sleep in cats. Brain Research 1973; 101: 569–575
   Web of Science ®Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Differentia] effects of pinealectomy on amygdala and hippocampus serotonin metabolism. Journal of Pineal Research 1991a; 10: 100–103
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat. Journal of Pineal Research 1991b; 11: 75–79
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F. J., Aldegunde M. Effects of single doses and daily melatonin treatments on serotonin metabolism in rat brain regions. Journal of Pineal Research 1994; 17: 170–176
   PubMed Web of Science ®Google Scholar
• Mitler M. M., Dement W. C. Sleep studies in canine narcolepsy: pattrn and cycle comparisons between affected and normal dogs. Electroencephalography and Clinical Neurophysiology 1977; 43: 691–699
   PubMedGoogle Scholar
• Molliver M. E. Serotonergic neuronal systems: what their anatomic organization tells us about function. Journal of Clinical Psychopharmacology 1987; 7: 3–23
   PubMed Web of Science ®Google Scholar
• Montplaisir J., Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 1986; 9: 280–284
   PubMed Web of Science ®Google Scholar
• Murdoch D., McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44: 604–624
   PubMed Web of Science ®Google Scholar
• Nagasaki H., Kosaka K., Nakamura R. Distribution of rhythm formation in patients with hemispheric lesion. Tohoku Journal of Experimental Medicine 1981; 135: 231–236
   PubMed Web of Science ®Google Scholar
• Nagatsu T., Wakui Y., Kato K. Dopamine beta-hydroxylase activity in cerebrospinal fluid of parkinsonian patients. Biomedical Research 1982; 3: 95–98
   Google Scholar
• Narabayashi H., Nakamura R. Clinical neurophysiology of freezing in parkinsonism. Clinical Neurophysiology in Parkinsonism, P. J. Delwaide, A. Agnoli. Elsevier, Amsterdam 1985; 49–57
   Google Scholar
• Narabayashi H., Kondo T., Hayashi A. L-threo-3, 4, -dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proceedings of the Japanese Academy 1981; 57: 351–354
   Google Scholar
• Narabayashi H., Kondo T., Nagatsu T. L-threo-3, 4-dihydroxyphenylserine treatment for freezing and akinesia in Parkinsonism. Neurology 1982; 32: A180
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Nagatsu T., Hayashi A., Suzuki T. DL-fhreo-3, 4-dihydroxyphenylser-ine for freezing symptom in parkinsonism. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 497–502
   Google Scholar
• Nausieda P., Weiner W. J., Kaplan L. R., Weber S., Klawans H. L. Sleep disruption in the course of levodopa therapy: an early feature of the levodopa psychosis. Clinical Neuropharmacology 1982; 5: 183–194
   PubMed Web of Science ®Google Scholar
• Nausieda P., Tanner C. M., Klawans H. L. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Advances in Neurology, S. Fahn, D. B. Calne, I. Shoulson. Raven Press, New York 1983; vol. 37: 23–32
   Google Scholar
• Nausieda P., Glantz R., Weber S., Baum R., Klawans H. L. Psychiatric complications of levodopa therapy of Parkinson's disease. Advances in Neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; vol. 40: 271–277
   Google Scholar
• Ng L. K. Y., Chase T. N., Colburn R. W., Kopin I. J. Dopa induced release of cerebral monoamines. Science 1970; 170: 76–77
   PubMed Web of Science ®Google Scholar
• Nutt J. G., Hammerstand J. P., Gancher S. T. Parkinson's Disease-100 Maxims. Edward Arnold, London 1992; 145–147
   Google Scholar
• Parkes J. D. Sleep and Its Disorders. W.B. Saunders, London 1985; 275–334
   Google Scholar
• Parkinson J. An essay on the Shaking Palsy. Sherwood, Neely and Jones, London 1817
   Google Scholar
• Pakkenberg H., Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurologica Scandinavica 1986; 73: 295–297
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Multiple serotonin receptors and their physiological significance. Federation Proceedings 1983; 42: 213–217
   PubMedGoogle Scholar
• Pompeiano O., Hoshino K. Central control of posture: reciprocal discharge by two pontine neuronal groups leading to suppression of decerebrate rigidity. Brain Research 1976; 116: 131–138
   PubMed Web of Science ®Google Scholar
• Pujol J. F. Interactions between serotonin and noradrenaline containing neurons: link between the raphe system and the locus coeruleus. Advances in Pharmacological Therapeutics, P. Simon. Pergamon Press, Oxford 1979; vol. 2: 417–429
   Google Scholar
• Reading P. J. Frontal lobe dysfunction in schizophrenia and Parkinson's disease- a meeting point for neurology, psychology and psychiatry: discussion paper. Journal of the Royal Society of Medicine 1991; 84: 349–353
   PubMed Web of Science ®Google Scholar
• Reches A. Noradrenergc influences on dopaminergic function and the pharmacology of dihydrophenylser-ine (DOPS): implications for Parkinson's disease. Clinical Neuropharmacology 1985; 8: 249–259
   PubMed Web of Science ®Google Scholar
• Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutrition and Metabolism 1980; 24: 417–423
   PubMedGoogle Scholar
• Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. Journal of Neural Transmission 1976; 38: 277–302
   PubMed Web of Science ®Google Scholar
• Rinne U. K. Fluctuations in disability during long-term levodopa treatment-advantages of early combination of bromocriptine and levodopa. Current Problems in Treatment of Parkinson's Disease, Y. Kuroiwa, Y. Toyokura. DMW, TokyoJapan 1985; 71–76
   Google Scholar
• Rinne U. K., Sonninen V. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology 1972; 22: 62–67
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of parkinsonism. International Journal of Neuroscience 1992b; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the ‘on-off’ phenomenon. International Journal of Neuroscience 1992c; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. A drug naive Parkinsonian patient succesfully treated with electromagnetic fields. International Journal of Neuroscience 1994a; 79: 99–110
   PubMed Web of Science ®Google Scholar
• Sandyk R. Reversal of a visuoconstructional deficit in report of five cases. International Journal of Neuroscience 1994b; 75: 213–228
   PubMed Web of Science ®Google Scholar
• Sandyk R. Application of weak electromagnetic fields facilitates sensory-motor integration in patients with multiple sclerosis. International Journal of Neuroscience, in press
   Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. L-tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience 1989a; 45: 215–219
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989b; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Sandyk R., Derpapas K. Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience 1993; 69: 167–183
   PubMedGoogle Scholar
• Sandyk R., Iacono R. P. Reversal of visual neglect in Parkinson's disease by treatment with picotesla range magnetic fields. International Journal of Neuroscience 1993; 73: 93–107
   PubMedGoogle Scholar
• Sandyk R., Anninos P. A., Tsagas N., Derpapas K. Magnetic fields in the treatment of Parkinson's disease. International Journal of Neuroscience 1992; 63: 141–150
   PubMed Web of Science ®Google Scholar
• Sano I., Taniguchi K. L-5-hydroxytryptophan (L-5-HTP)-therapie des Morbus Parkinson. Muenschen Medizinische Wochenschrift 1972; 114: 1717–1719
   PubMedGoogle Scholar
• Sawada M., Nagatsu T., Nagtsu I., Ito K., Iizuka R., Kondo T., Narabayashi H. Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients. Journal of Neural Transmission 1985; 62: 107–115
   PubMed Web of Science ®Google Scholar
• Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research 1983; 275: 321–328
   PubMed Web of Science ®Google Scholar
• Scatton B., Dennis T., L'heureux R., Monfort J. C, Duyckaerts C., Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Scrima L. An etiology of narcolepsy-cataplexy and a proposed cataplexy neuromechanism. International Journal of Neuroscience 1981; 15: 69–86
   PubMed Web of Science ®Google Scholar
• Selby G. Clinical features. Parkinson's Disease, G. M. Stern. Chapman and Hall Medical, London 1990; 349–353
   Google Scholar
• Semm P. Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology 1983; 76A: 683–689
   Web of Science ®Google Scholar
• Semm P., Vollrath L. Electrical responses of homing pigeon and guinea pig Purkinje cells to pineal indoleamines applied by microelectrophoresis. Journal of Comparative Physiology 1984; 154: 675–681
   Web of Science ®Google Scholar
• Semm P., Schneider T., Vollrath L. Effects of an earth-strength magnetic field on electrical activity of pineal cells. Nature 1980; 288: 607–608
   PubMed Web of Science ®Google Scholar
• Snider S., Hutt C., Stein B. Increase in brain serotonin produced by bromicryptine. Neuroscience Letters 1975; 1: 237–241
   Web of Science ®Google Scholar
• Souques A. Rapport sur les syndromes parkinsoniens. Revue Neurologique 1921; 37: 534–573
   Google Scholar
• Steinbusch H. W. M. Serotonergic immunoreactive neurons and their projections in the CNS. Classical Transmitter Receptors in the CNS. Handbook of Chemical Neuroanatomy, A. Bjorklund, T. Hokfelt, M. J. Kuhar. Elsevier, Amsterdam 1984; vol. 3: 68–125
   Google Scholar
• Steur E. N. H. J. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–213
   PubMed Web of Science ®Google Scholar
• Strang R. R. Imipramine in treatment of parkinsonism: a double blind placebo study. British Medical Journal 1965; 2: 33
   PubMedGoogle Scholar
• Sugden D., Morris R. D. Changes in regional brain levels of tryptophan, 5-hydroxytryptamine, 5-hy-droxyindoleacetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal of Neurochemistry 1979; 32: 1593–1595
   PubMed Web of Science ®Google Scholar
• Tohgi H., Abe T., Takahashi S., Ueno M., Nozaki Y. Cerebrospinal fluid dopamine, norepinephrine, and epinephrine concentrations in Parkinson's disease correlated with clinical symptoms. Advances in Neurology: Parkinson's Disease: Anatomy, Pathogenesis and Therapy, M. B. Streifler, A. D. Korczyn, E. Melamed, M. B. H. Youdim. Raven Press, New York 1990; vol. 53: 277–282
   Google Scholar
• Wallis D. I. 5-HT receptors involved in initiation or modulation of motor patterns: opportunities for drug development. Trends in Pharmacological Sciences 1994; 15: 288–292
   PubMed Web of Science ®Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C, Wiltschko W., Vollrath L. Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Chess E. K., Anderson L. E. 60-Hz electric-field effects on pineal melatonin rhythms: time course for onset and recovery. Bioelectromagnetics 1986; 7: 239–242
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Stevens R. G., Anderson L. E. Neuroendocrine mediated effects of electromagnetic field exposure: possible role of the pineal gland. Life Sciences 1989; 45: 1319–1332
   PubMed Web of Science ®Google Scholar
• Yanagisawa N., Fujimoto S., Ueno E. Neurophysiological aspecys of Parkinson's disease. Current Problems in Treatment of Parkinson's Disease, Y. Kuroiwa, Y. Toyokura. DMW, TokyoJapan 1985; 13–22
   Google Scholar
• Zbinden G. Pharmacodynamics of tetrabenazine and its derivatives. Psychosomatic Medicine, J. H. Nodine, J. H. Moyer. Lea and Febiger, Philadelphia 1962; 443–454
   Google Scholar